[108th Congress Public Law 130]
[From the U.S. Government Printing Office]
[DOCID: f:publ130.108]
[[Page 117 STAT. 1361]]
Public Law 108-130
108th Congress
An Act
To amend the Federal Food, Drug, and Cosmetic Act to establish a program
of fees relating to animal drugs. <<NOTE: Nov. 18, 2003 - [S. 313]>>
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress <<NOTE: Animal Drug User Fee Act of
2003.>> assembled,
SECTION 1. SHORT TITLE. <<NOTE: 21 USC 301 note.>>
This Act may be cited as the ``Animal Drug User Fee Act of 2003''.
SEC. 2. FINDINGS. <<NOTE: 21 USC 379j-11 note.>>
Congress finds as follows:
(1) Prompt approval of safe and effective new animal drugs
is critical to the improvement of animal health and the public
health.
(2) Animal health and the public health will be served by
making additional funds available for the purpose of augmenting
the resources of the Food and Drug Administration that are
devoted to the process for review of new animal drug
applications.
(3) The fees authorized by this Act will be dedicated toward
expediting the animal drug development process and the review of
new and supplemental animal drug applications and
investigational animal drug submissions as set forth in the
goals identified, for purposes of part 4 of subchapter C of
chapter VII of the Federal Food, Drug, and Cosmetic Act, in the
letters from the Secretary of Health and Human Services to the
Chairman of the Committee on Energy and Commerce of the House of
Representatives and the Chairman of the Committee on Health,
Education, Labor, and Pensions of the Senate as set forth in the
Congressional Record.
SEC. 3. FEES RELATING TO ANIMAL DRUGS.
Subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 379f et seq.) is amended by adding at the end the
following part:
``PART 4--FEES RELATING TO ANIMAL DRUGS
``SEC. 739. DEFINITIONS. <<NOTE: 21 USC 379j-11.>>
``For purposes of this subchapter:
``(1) The term `animal drug application' means an
application for approval of any new animal drug submitted under
section 512(b)(1). Such term does not include either a new
[[Page 117 STAT. 1362]]
animal drug application submitted under section 512(b)(2) or a
supplemental animal drug application.
``(2) The term `supplemental animal drug application'
means--
``(A) a request to the Secretary to approve a change
in an animal drug application which has been approved;
or
``(B) a request to the Secretary to approve a change
to an application approved under section 512(c)(2) for
which data with respect to safety or effectiveness are
required.
``(3) The term `animal drug product' means each specific
strength or potency of a particular active ingredient or
ingredients in final dosage form marketed by a particular
manufacturer or distributor, which is uniquely identified by the
labeler code and product code portions of the national drug
code, and for which an animal drug application or a supplemental
animal drug application has been approved.
``(4) The term `animal drug establishment' means a foreign
or domestic place of business which is at one general physical
location consisting of one or more buildings all of which are
within 5 miles of each other, at which one or more animal drug
products are manufactured in final dosage form.
``(5) The term `investigational animal drug submission'
means--
``(A) the filing of a claim for an investigational
exemption under section 512(j) for a new animal drug
intended to be the subject of an animal drug application
or a supplemental animal drug application, or
``(B) the submission of information for the purpose
of enabling the Secretary to evaluate the safety or
effectiveness of an animal drug application or
supplemental animal drug application in the event of
their filing.
``(6) The term `animal drug sponsor' means either an
applicant named in an animal drug application, except for an
approved application for which all subject products have been
removed from listing under section 510, or a person who has
submitted an investigational animal drug submission that has not
been terminated or otherwise rendered inactive by the Secretary.
``(7) The term `final dosage form' means, with respect to an
animal drug product, a finished dosage form which is approved
for administration to an animal without substantial further
manufacturing. Such term includes animal drug products intended
for mixing in animal feeds.
``(8) The term `process for the review of animal drug
applications' means the following activities of the Secretary
with respect to the review of animal drug applications,
supplemental animal drug applications, and investigational
animal drug submissions:
``(A) The activities necessary for the review of
animal drug applications, supplemental animal drug
applications, and investigational animal drug
submissions.
``(B) The issuance of action letters which approve
animal drug applications or supplemental animal drug
applications or which set forth in detail the specific
deficiencies in animal drug applications, supplemental
animal
[[Page 117 STAT. 1363]]
drug applications, or investigational animal drug
submissions and, where appropriate, the actions
necessary to place such applications, supplements or
submissions in condition for approval.
``(C) The inspection of animal drug establishments
and other facilities undertaken as part of the
Secretary's review of pending animal drug applications,
supplemental animal drug applications, and
investigational animal drug submissions.
``(D) Monitoring of research conducted in connection
with the review of animal drug applications,
supplemental animal drug applications, and
investigational animal drug submissions.
``(E) The development of regulations and policy
related to the review of animal drug applications,
supplemental animal drug applications, and
investigational animal drug submissions.
``(F) Development of standards for products subject
to review.
``(G) Meetings between the agency and the animal
drug sponsor.
``(H) Review of advertising and labeling prior to
approval of an animal drug application or supplemental
animal drug application, but not such activities after
an animal drug has been approved.
``(9) The term `costs of resources allocated for the process
for the review of animal drug applications' means the expenses
incurred in connection with the process for the review of animal
drug applications for--
``(A) officers and employees of the Food and Drug
Administration, contractors of the Food and Drug
Administration, advisory committees consulted with
respect to the review of specific animal drug
applications, supplemental animal drug applications, or
investigational animal drug submissions, and costs
related to such officers, employees, committees, and
contractors, including costs for travel, education, and
recruitment and other personnel activities,
``(B) management of information, and the
acquisition, maintenance, and repair of computer
resources,
``(C) leasing, maintenance, renovation, and repair
of facilities and acquisition, maintenance, and repair
of fixtures, furniture, scientific equipment, and other
necessary materials and supplies, and
``(D) collecting fees under section 740 and
accounting for resources allocated for the review of
animal drug applications, supplemental animal drug
applications, and investigational animal drug
submissions.
``(10) The term `adjustment factor' applicable to a fiscal
year refers to the formula set forth in section 735(8) with the
base or comparator year being 2003.
``(11) The term `affiliate' refers to the definition set
forth in section 735(9).
``SEC. 740. AUTHORITY TO ASSESS AND USE ANIMAL DRUG FEES. <<NOTE: 21 USC
379j-12.>>
``(a) Types of Fees.--Beginning in fiscal year 2004, the Secretary
shall assess and collect fees in accordance with this section as
follows:
[[Page 117 STAT. 1364]]
``(1) Animal drug application and supplement fee.--
``(A) In general.--Each person that submits, on or
after September 1, 2003, an animal drug application or a
supplemental animal drug application shall be subject to
a fee as follows:
``(i) A fee established in subsection (b) for
an animal drug application; and
``(ii) A fee established in subsection (b) for
a supplemental animal drug application for which
safety or effectiveness data are required, in an
amount that is equal to 50 percent of the amount
of the fee under clause (i).
``(B) Payment.--The fee required by subparagraph (A)
shall be due upon submission of the animal drug
application or supplemental animal drug application.
``(C) Exception for previously filed application or
supplement.--If an animal drug application or a
supplemental animal drug application was submitted by a
person that paid the fee for such application or
supplement, was accepted for filing, and was not
approved or was withdrawn (without a waiver or refund),
the submission of an animal drug application or a
supplemental animal drug application for the same
product by the same person (or the person's licensee,
assignee, or successor) shall not be subject to a fee
under subparagraph (A).
``(D) Refund of fee if application refused for
filing.--The Secretary shall refund 75 percent of the
fee paid under subparagraph (B) for any animal drug
application or supplemental animal drug application
which is refused for filing.
``(E) Refund of fee if application withdrawn.--If an
animal drug application or a supplemental animal drug
application is withdrawn after the application or
supplement was filed, the Secretary may refund the fee
or portion of the fee paid under subparagraph (B) if no
substantial work was performed on the application or
supplement after the application or supplement was
filed. The Secretary shall have the sole discretion to
refund the fee under this paragraph. A determination by
the Secretary concerning a refund under this paragraph
shall not be reviewable.
``(2) Animal drug product fee.--Each person--
``(A) who is named as the applicant in an animal
drug application or supplemental animal drug application
for an animal drug product which has been submitted for
listing under section 510, and
``(B) who, after September 1, 2003, had pending
before the Secretary an animal drug application or
supplemental animal drug application;
shall pay for each such animal drug product the annual fee
established in subsection (b). Such fee shall be payable for the
fiscal year in which the animal drug product is first submitted
for listing under section 510, or is submitted for relisting
under section 510 if the animal drug product has been withdrawn
from listing and relisted. <<NOTE: Deadline.>> After such fee is
paid for that fiscal year, such fee shall be payable on or
before January
[[Page 117 STAT. 1365]]
31 of each year. Such fee shall be paid only once for each
animal drug product for a fiscal year in which the fee is
payable.
``(3) Animal drug establishment fee.--Each person--
``(A) who owns or operates, directly or through an
affiliate, an animal drug establishment, and
``(B) who is named as the applicant in an animal
drug application or supplemental animal drug application
for an animal drug product which has been submitted for
listing under section 510, and
``(C) who, after September 1, 2003, had pending
before the Secretary an animal drug application or
supplemental animal drug application,
shall be assessed an annual fee established in subsection (b)
for each animal drug establishment listed in its approved animal
drug application as an establishment that manufactures the
animal drug product named in the application. The annual
establishment fee shall be assessed in each fiscal year in which
the animal drug product named in the application is assessed a
fee under paragraph (2) unless the animal drug establishment
listed in the application does not engage in the manufacture of
the animal drug product during the fiscal
year. <<NOTE: Deadline.>> The fee shall be paid on or before
January 31 of each year. The establishment shall be assessed
only one fee per fiscal year under this section: Provided,
however, That where a single establishment manufactures both
animal drug products and prescription drug products, as defined
in section 735(3), such establishment shall be assessed both the
animal drug establishment fee and the prescription drug
establishment fee, as set forth in section 736(a)(2), within a
single fiscal year.
``(4) Animal drug sponsor fee.--Each person--
``(A) who meets the definition of an animal drug
sponsor within a fiscal year; and
``(B) who, after September 1, 2003, had pending
before the Secretary an animal drug application, a
supplemental animal drug application, or an
investigational animal drug submission,
shall be assessed an annual fee established under subsection
(b). <<NOTE: Deadline.>> The fee shall be paid on or before
January 31 of each year. Each animal drug sponsor shall pay only
one such fee each fiscal year.
``(b) Fee Amounts.--Except as provided in subsection (a)(1) and
subsections (c), (d), (f), and (g), the fees required under subsection
(a) shall be established to generate fee revenue amounts as follows:
``(1) Total fee revenues for application and supplement
fees.--The total fee revenues to be collected in animal drug
application fees under subsection (a)(1)(A)(i) and supplemental
animal drug application fees under subsection (a)(1)(A)(ii)
shall be $1,250,000 in fiscal year 2004, $2,000,000 in fiscal
year 2005, and $2,500,000 in fiscal years 2006, 2007, and 2008.
``(2) Total fee revenues for product fees.--The total fee
revenues to be collected in product fees under subsection (a)(2)
shall be $1,250,000 in fiscal year 2004, $2,000,000 in fiscal
year 2005, and $2,500,000 in fiscal years 2006, 2007, and 2008.
[[Page 117 STAT. 1366]]
``(3) Total fee revenues for establishment fees.--The total
fee revenues to be collected in establishment fees under
subsection (a)(3) shall be $1,250,000 in fiscal year 2004,
$2,000,000 in fiscal year 2005, and $2,500,000 in fiscal years
2006, 2007, and 2008.
``(4) Total fee revenues for sponsor fees.--The total fee
revenues to be collected in sponsor fees under subsection (a)(4)
shall be $1,250,000 in fiscal year 2004, $2,000,000 in fiscal
year 2005, and $2,500,000 in fiscal years 2006, 2007, and 2008.
``(c) Adjustments.--
``(1) <<NOTE: Federal Register, publication.>> Inflation
adjustment.--The revenues established in subsection (b) shall be
adjusted by the Secretary by notice, published in the Federal
Register, for a fiscal year to reflect the greater of--
``(A) the total percentage change that occurred in
the Consumer Price Index for all urban consumers (all
items; United States city average) for the 12-month
period ending June 30 preceding the fiscal year for
which fees are being established; or
``(B) the total percentage change for the previous
fiscal year in basic pay under the General Schedule in
accordance with section 5332 of title 5, United States
Code, as adjusted by any locality-based comparability
payment pursuant to section 5304 of such title for
Federal employees stationed in the District of Columbia.
The adjustment made each fiscal year by this subsection will be
added on a compounded basis to the sum of all adjustments made
each fiscal year after fiscal year 2004 under this subsection.
``(2) Workload adjustment.--After the fee revenues are
adjusted for inflation in accordance with paragraph (1), the fee
revenues shall be further adjusted each fiscal year after fiscal
year 2004 to reflect changes in review workload. With respect to
such adjustment:
``(A) This adjustment shall be determined by the
Secretary based on a weighted average of the change in
the total number of animal drug applications,
supplemental animal drug applications for which data
with respect to safety or effectiveness are required,
manufacturing supplemental animal drug applications,
investigational animal drug study submissions, and
investigational animal drug protocol submissions
submitted to the Secretary. <<NOTE: Federal Register,
publication.>> The Secretary shall publish in the
Federal Register the fees resulting from this adjustment
and the supporting methodologies.
``(B) Under no circumstances shall this workload
adjustment result in fee revenues for a fiscal year that
are less than the fee revenues for that fiscal year
established in subsection (b), as adjusted for inflation
under paragraph (1).
``(3) Final year adjustment.--For fiscal year 2008, the
Secretary may further increase the fees to provide for up to 3
months of operating reserves of carryover user fees for the
process for the review of animal drug applications for the first
3 months of fiscal year 2009. If the Food and Drug
Administration has carryover balances for the process for the
[[Page 117 STAT. 1367]]
review of animal drug applications in excess of 3 months of such
operating reserves, then this adjustment will not be made. If
this adjustment is necessary, then the rationale for the amount
of the increase shall be contained in the annual notice setting
fees for fiscal year 2008.
``(4) <<NOTE: Deadline.>> Annual fee setting.--The Secretary
shall establish, 60 days before the start of each fiscal year
beginning after September 30, 2003, for that fiscal year, animal
drug application fees, supplemental animal drug application
fees, animal drug sponsor fees, animal drug establishment fees,
and animal drug product fees based on the revenue amounts
established under subsection (b) and the adjustments provided
under this subsection.
``(5) Limit.--The total amount of fees charged, as adjusted
under this subsection, for a fiscal year may not exceed the
total costs for such fiscal year for the resources allocated for
the process for the review of animal drug applications.
``(d) Fee Waiver or Reduction.--
``(1) In general.--The Secretary shall grant a waiver from
or a reduction of 1 or more fees assessed under subsection (a)
where the Secretary finds that--
``(A) the assessment of the fee would present a
significant barrier to innovation because of limited
resources available to such person or other
circumstances,
``(B) the fees to be paid by such person will exceed
the anticipated present and future costs incurred by the
Secretary in conducting the process for the review of
animal drug applications for such person,
``(C) the animal drug application or supplemental
animal drug application is intended solely to provide
for use of the animal drug in--
``(i) a Type B medicated feed (as defined in
section 558.3(b)(3) of title 21, Code of Federal
Regulations (or any successor regulation))
intended for use in the manufacture of Type C
free-choice medicated feeds, or
``(ii) a Type C free-choice medicated feed (as
defined in section 558.3(b)(4) of title 21, Code
of Federal Regulations (or any successor
regulation)),
``(D) the animal drug application or supplemental
animal drug application is intended solely to provide
for a minor use or minor species indication, or
``(E) the sponsor involved is a small business
submitting its first animal drug application to the
Secretary for review.
``(2) Use of standard costs.--In making the finding in
paragraph (1)(B), the Secretary may use standard costs.
``(3) Rules for small businesses.--
``(A) Definition.--In paragraph (1)(E), the term
`small business' means an entity that has fewer than 500
employees, including employees of affiliates.
``(B) Waiver of application fee.--The Secretary
shall waive under paragraph (1)(E) the application fee
for the first animal drug application that a small
business or its affiliate submits to the Secretary for
review. After a small business or its affiliate is
granted such a waiver, the small business or its
affiliate shall pay application fees for all
[[Page 117 STAT. 1368]]
subsequent animal drug applications and supplemental
animal drug applications for which safety or
effectiveness data are required in the same manner as an
entity that does not qualify as a small business.
``(C) Certification.--The Secretary shall require
any person who applies for a waiver under paragraph
(1)(E) to certify their qualification for the
waiver. <<NOTE: Federal Register, publication.>> The
Secretary shall periodically publish in the Federal
Register a list of persons making such certifications.
``(e) Effect of Failure To Pay Fees.--An animal drug application or
supplemental animal drug application submitted by a person subject to
fees under subsection (a) shall be considered incomplete and shall not
be accepted for filing by the Secretary until all fees owed by such
person have been paid. An investigational animal drug submission under
section 739(5)(B) that is submitted by a person subject to fees under
subsection (a) shall be considered incomplete and shall not be accepted
for review by the Secretary until all fees owed by such person have been
paid. The Secretary may discontinue review of any animal drug
application, supplemental animal drug application or investigational
animal drug submission from a person if such person has not submitted
for payment all fees owed under this section by 30 days after the date
upon which they are due.
``(f) Assessment of Fees.--
``(1) Limitation.--Fees may not be assessed under subsection
(a) for a fiscal year beginning after fiscal year 2003 unless
appropriations for salaries and expenses of the Food and Drug
Administration for such fiscal year (excluding the amount of
fees appropriated for such fiscal year) are equal to or greater
than the amount of appropriations for the salaries and expenses
of the Food and Drug Administration for the fiscal year 2003
(excluding the amount of fees appropriated for such fiscal year)
multiplied by the adjustment factor applicable to the fiscal
year involved.
``(2) Authority.--If the Secretary does not assess fees
under subsection (a) during any portion of a fiscal year because
of paragraph (1) and if at a later date in such fiscal year the
Secretary may assess such fees, the Secretary may assess and
collect such fees, without any modification in the rate, for
animal drug applications, supplemental animal drug applications,
investigational animal drug submissions, animal drug sponsors,
animal drug establishments and animal drug products at any time
in such fiscal year notwithstanding the provisions of subsection
(a) relating to the date fees are to be paid.
``(g) Crediting and Availability of Fees.--
``(1) In general.--Fees authorized under subsection (a)
shall be collected and available for obligation only to the
extent and in the amount provided in advance in appropriations
Acts. Such fees are authorized to be appropriated to remain
available until expended. Such sums as may be necessary may be
transferred from the Food and Drug Administration salaries and
expenses appropriation account without fiscal year limitation to
such appropriation account for salary and expenses with such
fiscal year limitation. The sums transferred shall be available
solely for the process for the review of animal drug
applications.
[[Page 117 STAT. 1369]]
``(2) Collections and appropriation acts.--
``(A) In general.--The fees authorized by this
section--
``(i) shall be retained in each fiscal year in
an amount not to exceed the amount specified in
appropriation Acts, or otherwise made available
for obligation for such fiscal year, and
``(ii) shall only be collected and available
to defray increases in the costs of the resources
allocated for the process for the review of animal
drug applications (including increases in such
costs for an additional number of full-time
equivalent positions in the Department of Health
and Human Services to be engaged in such process)
over such costs, excluding costs paid from fees
collected under this section, for fiscal year 2003
multiplied by the adjustment factor.
``(B) Compliance.--The Secretary shall be considered
to have met the requirements of subparagraph (A)(ii) in
any fiscal year if the costs funded by appropriations
and allocated for the process for the review of animal
drug applications--
``(i) are not more than 3 percent below the
level specified in subparagraph (A)(ii); or
``(ii)(I) are more than 3 percent below the
level specified in subparagraph (A)(ii), and fees
assessed for the fiscal year following the
subsequent fiscal year are decreased by the amount
in excess of 3 percent by which such costs fell
below the level specified in subparagraph (A)(ii);
and
``(II) such costs are not more than 5 percent
below the level specified in subparagraph (A)(ii).
``(3) Authorization of appropriations.--There are authorized
to be appropriated for fees under this section--
``(A) $5,000,000 for fiscal year 2004;
``(B) $8,000,000 for fiscal year 2005;
``(C) $10,000,000 for fiscal year 2006;
``(D) $10,000,000 for fiscal year 2007; and
``(E) $10,000,000 for fiscal year 2008;
as adjusted to reflect adjustments in the total fee revenues
made under this section and changes in the total amounts
collected by animal drug application fees, supplemental animal
drug application fees, animal drug sponsor fees, animal drug
establishment fees, and animal drug product fees.
``(4) Offset.--Any amount of fees collected for a fiscal
year under this section that exceeds the amount of fees
specified in appropriations Acts for such fiscal year shall be
credited to the appropriation account of the Food and Drug
Administration as provided in paragraph (1), and shall be
subtracted from the amount of fees that would otherwise be
authorized to be collected under this section pursuant to
appropriation Acts for a subsequent fiscal year.
``(h) Collection of Unpaid Fees.--In any case where the Secretary
does not receive payment of a fee assessed under subsection (a) within
30 days after it is due, such fee shall be treated as a claim of the
United States Government subject to subchapter II of chapter 37 of title
31, United States Code.
[[Page 117 STAT. 1370]]
``(i) <<NOTE: Deadline.>> Written Requests for Waivers, Reductions,
and Refunds.--To qualify for consideration for a waiver or reduction
under subsection (d), or for a refund of any fee collected in accordance
with subsection (a), a person shall submit to the Secretary a written
request for such waiver, reduction, or refund not later than 180 days
after such fee is due.
``(j) Construction.--This section may not be construed to require
that the number of full-time equivalent positions in the Department of
Health and Human Services, for officers, employees, and advisory
committees not engaged in the process of the review of animal drug
applications, be reduced to offset the number of officers, employees,
and advisory committees so engaged.
``(k) Abbreviated New Animal Drug Applications.--The Secretary
shall--
``(1) to the extent practicable, segregate the review of
abbreviated new animal drug applications from the process for
the review of animal drug applications, and
``(2) adopt other administrative procedures to ensure that
review times of abbreviated new animal drug applications do not
increase from their current level due to activities under the
user fee program.''.
SEC. 4. ACCOUNTABILITY AND REPORTS. <<NOTE: 21 USC 379j-11 note.>>
(a) Public Accountability.--
(1) Consultation.--In developing recommendations to Congress
for the goals and plans for meeting the goals for the process
for the review of animal drug applications for the fiscal years
after fiscal year 2008, and for the reauthorization of sections
739 and 740 of the Federal Food, Drug, and Cosmetic Act (as
added by section 3), the Secretary of Health and Human Services
(referred to in this section as the ``Secretary'') shall consult
with the Committee on Energy and Commerce of the House of
Representatives, the Committee on Health, Education, Labor, and
Pensions of the Senate, appropriate scientific and academic
experts, veterinary professionals, representatives of consumer
advocacy groups, and the regulated industry.
(2) Recommendations.--The Secretary shall--
(A) <<NOTE: Federal Register, publication.>> publish
in the Federal Register recommendations under paragraph
(1), after negotiations with the regulated industry;
(B) present the recommendations to the Committees
referred to in that paragraph;
(C) hold a meeting at which the public may comment
on the recommendations; and
(D) provide for a period of 30 days for the public
to provide written comments on the recommendations.
(b) <<NOTE: Deadline.>> Performance Reports.--Beginning with fiscal
year 2004, not later than 60 days after the end of each fiscal year
during which fees are collected under part 4 of subchapter C of chapter
VII of the Federal Food, Drug, and Cosmetic Act, the Secretary shall
prepare and submit to the Committee on Energy and Commerce of the House
of Representatives and the Committee on Health, Education, Labor, and
Pensions of the Senate a report concerning the progress of the Food and
Drug Administration in achieving the goals identified in the letters
described in section 2(3) of this Act toward expediting the animal drug
development
[[Page 117 STAT. 1371]]
process and the review of the new and supplemental animal drug
applications and investigational animal drug submissions during such
fiscal year, the future plans of the Food and Drug Administration for
meeting the goals, the review times for abbreviated new animal drug
applications, and the administrative procedures adopted by the Food and
Drug Administration to ensure that review times for abbreviated new
animal drug applications are not increased from their current level due
to activities under the user fee program.
(c) <<NOTE: Deadline.>> Fiscal Report.--Beginning with fiscal year
2004, not later than 120 days after the end of each fiscal year during
which fees are collected under the part described in subsection (b), the
Secretary shall prepare and submit to the Committee on Energy and
Commerce of the House of Representatives and the Committee on Health,
Education, Labor, and Pensions of the Senate a report on the
implementation of the authority for such fees during such fiscal year
and the use, by the Food and Drug Administration, of the fees collected
during such fiscal year for which the report is made.
SEC. 5. SUNSET. <<NOTE: 21 USC 379j-11 note.>>
The amendments made by section 3 shall not be in effect after
October 1, 2008, and section 4 shall not be in effect after 120 days
after such date.
Approved November 18, 2003.
LEGISLATIVE HISTORY--S. 313:
---------------------------------------------------------------------------
SENATE REPORTS: No. 108-51 (Comm. on Health, Education, Labor, and
Pensions).
CONGRESSIONAL RECORD, Vol. 149 (2003):
May 23, considered and passed Senate.
June 3, passage vitiated; reconsidered and passed Senate.
Nov. 4, considered and passed House, amended.
Nov. 7, Senate concurred in House amendment.
WEEKLY COMPILATION OF PRESIDENTIAL DOCUMENTS, Vol. 39 (2003):
Nov. 18, Presidential statement.
<all>